EXTENDED REPORT

AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis

Cleo S Bonnet,1 Anwen S Williams,2 Sophie J Gilbert,1 Ann K Harvey,3 Bronwen A Evans,4 Deborah J Mason5

ABSTRACT

Objectives Synovial fluid glutamate concentrations increase in arthritis. Activation of kainate (KA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors (GluRs) increase interleukin-6 (IL-6) release and cause articular pain, respectively. We hypothesised that AMPA and KA GluRs are expressed in human arthritis, and that intra-articular NBQX (AMPA/KA GluR antagonist) prevents pain and pathology in antigen-induced arthritis (AIA).

Methods GluR immunohistochemistry was related to synovial inflammation and degradation in osteoarthritis (OA) and rheumatoid arthritis (RA). A single intra-articular NBQX injection was given at induction, and knee swelling and gait of AIA and AIA+NBQX rats compared over 21 days, before imaging, RT-qPCR, histology and immunohistochemistry of joints. Effects of NBQX on human primary osteoblast (HOB) activity were determined.

Results AMPAR2 and KA1 immunolocalised to remodelling bone, cartilage and synovial cells in human OA and RA, and rat AIA. All arthritic tissues showed degradation and synovial inflammation. NBQX reduced GluR abundance, knee swelling (p<0.001, days 1–21), gait abnormalities (days 1–2), end-stage joint destruction (p<0.001), synovial inflammation (p<0.001), and messenger RNA expression of mensical IL-6 (p<0.05) and whole joint cathepsin K (p<0.01). X-ray and MRI revealed fewer cartilage and bone erosions, and less inflammation after NBQX treatment. NBQX reduced HOB number and prevented mineralisation.

Conclusions AMPA/KA GluRs are expressed in human OA and RA, and in AIA, where a single intra-articular injection of NBQX reduced swelling by 33%, and inflammation and degeneration scores by 34% and 27%, respectively, exceeding the efficacy of approved drugs in the same model. AMPA/KA GluR antagonists represent a potential treatment for arthritis.

INTRODUCTION

Inflammation underlies pathology in osteoarthritis (OA)1–3 and rheumatoid arthritis (RA).4 Non-steroidal anti-inflammatory drugs, corticosteroids and anti-cytokine treatments that have revolutionised RA treatment6 also relieve OA symptoms with varying success.5–9 Here, we investigate whether glutamate receptor (GluR) antagonists represent a new treatment targeting inflammatory stages of arthritis.

Synovial fluid (SF) glutamate concentrations increase 52-fold in RA (326 μM) and 42-fold in OA (266 μM)10 and in arthritis animal models.11 12 In RA, high SF glutamate correlates with increased inflammatory mediators.13 14 Glutamate is now known to signal in various ‘non-excitable’ cells,15–17 being released by nerves, macrophages, lymphocytes, synoviocytes, osteoblasts, osteoclasts and chondrocytes,11 14 18 19 and acting on ionotropic glutamate receptors (iGluRs) and metabotropic GluRs in multiple joint cell types.18 20 21 GluRs regulate peripheral pain,22 cytokine and matrix metalloproteinase (MMP) release,20 synoviocyte proliferation23 24 and immune responses.21 Therefore, GluR antagonists represent potential drugs with multimodal activity against arthritis symptoms.

Intra-articular injections of iGluR antagonists have been shown to inhibit pain for 24 h in murine carrageenan-induced arthritis (MK801, NBQX),25 suppress inflammatory pain for 24 h in arthritic mice (GYKI 52466, 1-NAS)26 and alleviate allodynia over 7 days in complete Freund’s adjuvant (CFA)-induced arthritis when combined with a substance P receptor antagonist and dexamethasone.27 Of two studies investigating the effects of GluR antagonists on arthritic pathology, one showed that a single intra-articular treatment targeting all iGluRs did not affect cartilage erosion in CFA arthritis,27 and the other revealed that continual systemic administration of memantine (N-methyl-D-aspartate receptor (NMDAR) antagonist) alleviated synovitis and joint destruction in collagen-induced arthritis (CIA).21 Long-term effects of single treatments of GluR antagonists on arthritic pain, inflammation and pathology are unknown, and no studies have investigated the pathological effects of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate (KA) GluR antagonists.

Since SF glutamate concentrations increase immediately after arthritis induction,11 AMPA GluRs mediate arthritic pain26 and KA GluR activation causes interleukin-6 (IL-6) release,20 a critical mediator of arthritic joint destruction,28 we hypothesised that early intra-articular intervention with NBQX (AMPA/KA GluR antagonist) would reduce pain, inflammation and pathology in inflammatory arthritis. The antigen-induced arthritis (AIA) rat model was used as it shares pathological features of human inflammatory arthritis,29 has defined IL-6 release profiles29 and does not require
analgesia. NBQX was administered at arthritis induction, prior to peak IL-6 concentrations, and gait, knee swelling, synovial inflammation, GluR expression and joint degeneration determined. To assess relevance to inflammatory processes in human arthritis, we investigated AMPA and KA GluR expression in human RA and OA knees.

**METHODS**

**Patients**

Matched synovium and medial tibial plateaux (MTP) were obtained (informed consent, Ref: 10/MRE0928) from randomly selected patients undergoing total knee replacement for OA (two women, one man) or RA (one man).

**Animals**

Procedures were performed according to Home Office guidelines on male Lewis rats (~200 g, Harlan, UK) housed in groups of three (12 h light–dark cycles, ad libitum food and water).

**Arthritis and treatments**

After two subcutaneous injections of methylated bovine serum albumin (mBSA; 0.5 mg/mL; Sigma) emulsified with an equal volume of CFA (0.25 mg Mycobacterium tuberculosis, Sigma) 7 days apart, AIA was induced by a single intra-articular injection (in 50 µL saline) into the right knee 14 days later (day 0). Induction was either with 0.5 mg mBSA alone (15 rats, AIA) or 0.5 mg mBSA+2.5 mM NBQX (Tocris) (15 rats, AIA+NBQX). The main comparisons in this intervention study were between AIA and AIA+NBQX rats, but naive rats (n=6) revealed effects of AIA. All measurements were taken at days 0 (baseline), 1, 2, 3, 4, 7, 9, 14 and 21, unless stated.

**Sample processing**

Human synovium, MTP and whole rat knees were fixed (2 days, 10% neutral buffered formalin, Sigma), decalciﬁed (4°C, 10% EDTA, Fisher Scientiﬁc), parafﬁn embedded and coronally sectioned (6 μm).

**Histology**

Consecutive sections from all human samples and nine AIA, nine AIA+NBQX and three naive rats (day 21) were stained with H&E (synovial inﬂammation), toluidine blue/safranin-O (cartilage and bone) or retained for immunohistochemistry.

Two independent observers blinded to treatment used published scoring systems to assess human OA and rat arthritis, we investigated AMPA and KA GluR expression in human RA and OA knees.

**Immunohistochemistry and TRAP staining**

GluRs were immunolocalised in sequential sections from human synovium, human MTP and rat knees (numbers as above) using antibodies to KA receptor-1 and AMPA receptor-2 (AMPAR2) (anti-KA1, anti-iGluR2; Abcam, see online supplementary methods). Sections underwent antigen retrieval (1 mg/mL trypsin, Sigma), peroxidase blocking, overnight incubation (4°C) with primary antibody and detection (Vectastain Elite ABC kit, nickel enhanced diaminobenzidine, Vector Laboratories). No primary antibody and IgG controls were included in every run (see online supplementary figure S1). Consecutive sections were tartrate resistant acid phosphatase (TRAP) stained (see online supplementary methods).

**Knee swelling**

Rat knee diameters were measured (mean of three readings per knee, Mitutoyo digital calliper, RS Components) and the difference between inﬂamed and contralateral knees presented.

**IL-6 ELISA**

Serum IL-6 concentrations were quantiﬁed from tail bleeds (six AIA, six AIA+NBQX, days 0, 1, 2, 3, 7, 14 and 21) (IL-6 Quantikine ELISA, R&D Systems).

**Footprint scoring**

Following training, walking patterns were evaluated by hind-footprint analysis (six AIA, six AIA+NBQX, three naive rats). Paws were dipped in paint prior to free movement along a paper-lined walkway (1 m long, 10 cm wide). Three sets of six sequential steps were recorded per rat per day. Limb rotation, stride length and stance width were measured.

**Imaging**

Whole rat knees (day 21) underwent X-ray and MRI. X-rays of both knees (nine AIA, nine AIA+NBQX, three naive) were obtained using a Kodak FX Pro In-vivo Imaging System (Advanced Molecular Vision). For MRI, both knees (six AIA, six AIA+NBQX) were imaged (Bruker Biospin Advance 9.4 T (400 mHz) system, transmit-receive quadrature coil, RARE-MRI sequence: TE=1250 ms, TR=24 ms, FA=180°, matrix size=580×280×280, FOV=58×28×28 mm) and 3D datasets manipulated to obtain representative mid-sagittal planes of each knee (Analyze 10.0, Mayo Clinic, Rochester).

**mRNA expression**

Menisci, patella, femoral shaft (FS), femoral condyle (FC) and tibial plateaux (TP) were dissected from both knees (six AIA, six AIA+NBQX, day 21). Total RNA was extracted (TRIzol, Invitrogen), DNase treated (DNA-free, Ambion), 300 ng reverse transcribed (SuperScript III, Invitrogen; ribonuclease inhibitor and random primers, Promega) and messenger RNA (mRNA) expression quantiﬁed by RT-qPCR (SYBR Green JumpStart Taq ReadyMix, Sigma; Stratagene MX3000P) using intron-spanning primers (Primer 3) (see online supplementary table S5). Sequencing of cloned RT-PCR products conﬁrmed primer speciﬁcity.

Standard curves for GluRs and IL-6 were generated from rat brain and spleen cDNAs, respectively, to conﬁrm linearity (R²≥0.95) and efﬁciency (90%–110%) for relative quantiﬁcation.

Absolute RT-qPCR (see online supplementary table S5) quantiﬁed osteoprotegerin (OPG), receptor activator of nuclear factor κ-B ligand (RANKL), cathepsin K and collagen type I alpha (COL1A1) mRNA in FC and TP using standard curves (10⁻¹–10⁻⁷ copies/µL) of RT-PCR products cloned in pGEM-T (Promega).

NormFinder identiﬁed the optimal combinations of reference genes (GAPDH, HPRT1, eEF2 and YWHAZ) for normalisation.

**Osteoblast assays**

The effects of NBQX (200 μM) on cell number and mineralisation of human primary osteoblasts (HOBs) from OA total knee replacement bone (three patients) were assessed by an MTS assay (Promega) (12 replicates/patient) and Alizarin Red S staining (20 days mineralisation culture, four replicates/patient) respectively (see online supplementary methods).
Figure 1  Representative human OA sample showing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 2 (AMPAR2) and KA1 immunohistochemistry in the medial tibial plateaux (MTP). (A), (C) and (D) are all images from the same location in the outer MTP. (A) Safranin-O stain reveals the architecture of the bone and cartilage, with extensive bone remodelling (BR) and breaching (TMB) of the tidemark (TM), which is almost completely lost. (B) Synovial tissue from the same patients showed evidence of inflammation indicated by perivascular lymphoid aggregates (open arrow) and a thickened synovial lining (small arrow). (C) AMPAR2 was localised to areas of remodelling, particularly to the TMB regions (arrows). (E) Osteocyte AMPAR2 staining was occasionally observed in small areas (arrow); however, many osteocytes remained negative (arrow head). No AMPAR2 staining was seen in osteoclasts (arrow head (F)) or bone lining cells (arrow head (G)) from normal areas of bone. (D) KA1 localised to remodelling bone (arrows), osteoclasts (arrow (I)) and osteoblasts (arrow (J)). No KA1 staining was seen in osteocytes (arrow head (H)). (K, L) AMPAR2 stained chondrocytes (arrow (M)) near the fibrillated cartilage surface down to the middle/deep zone interface, appearing strongest in the middle zone, with no staining near the TM (indicated by arrows). (N, O) KA1 stained chondrocytes (arrow (P)) near the surface to the upper middle zone, with no staining in the deep zone. Corresponding negative controls (no primary antibody) and rabbit IgG controls were negative for KA1 and AMPAR2 (see online supplementary figure S1). Boxes indicate where higher power image was taken. Scale bars: (A–D), 200 μm; (E, G, J, M, P), 50 μm; (F, H, I), 25 μm; (K, N), 500 μm; (L, O), 100 μm.
Statistics
Using Minitab 16, data were tested for normality and equal variances prior to ANOVA (histological inflammation (Fisher’s) and COL1A1, RANKL, OPG mRNA expression (Tukey–Kramer) or general linear model two-way ANOVA (GluR mRNA expression (Tukey–Kramer)) with individual post hoc tests. Two sample t tests were used for cell number. Non-parametric data used Kruskal–Wallis (footprints, histological joint degradation, IL-6 and cathepsin K mRNA expression) or Sheirer–Ray–Hare (knee swelling, joint compartment degradation) with Mann–Whitney post hoc tests. Means±SE of the mean (SEM) are presented.

RESULTS
GluRs are expressed in human arthritis
All patients showed cartilage fibrillation, tidemark breaches and proteoglycan loss, with OA MTP degradation scores ranging from 9 to 13 (figure 1A, see online supplementary figure S2). Synovial inflammation occurred in OA samples, with scores of 1–2 (figure 1B).

In OA, AMPAR2 localised to mononuclear cells (including some osteocytes) in areas of bone remodelling (figure 1C,E), but not osteoclasts (figure 1F). KA1 localised to remodelling bone (figure 1D), osteoclasts (figure 1I) and osteoblasts (figure 1J) but not to osteocytes (figure 1H). Chondrocytes expressed both receptors, with more staining near the cartilage surface and none in the deep zone (figure 1K–P). AMPAR2 and KA1 immunopositive chondrocytes were abundant in the middle section of MTP cartilage but less common in the severely degraded outer MTP cartilage (see online supplementary figure S2). AMPAR2 and KA1 staining in the bone localised mainly to remodelling bone in the outer segment of the MTP (see online supplementary figure S2). Similar patterns occurred in RA, with KA1 and AMPAR2 present in osteoclasts (see online supplementary figure S3).

AIA and NBQX influence GluR expression
KA1 and AMPAR2 proteins were expressed in chondrocytes and synovial lining cells (not shown) in all rats, and localised to remodelling bone in AIA and AIA+NBQX (figure 2).

Figure 2  KA1 and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 2 (AMPAR2) immunohistochemistry and tartrate resistant acid phosphatase (TRAP) staining in the lateral femoral condyle of naive, antigen-induced arthritis (AIA) and AIA+NBQX rats. Chondrocytes in all animals expressed KA1 and AMPAR2 (A–C, G–I, respectively, black arrows). Neither proteins localised to osteocytes or mononuclear bone cells (D, J, red arrow heads) in naive rats; however, in AIA and AIA+NBQX rats, AMPAR2 was expressed in osteocytes, mainly in areas of bone remodelling (K, L, red arrow). In AIA rats, mononuclear bone cells and areas of bone remodelling stained intensely for KA1 and AMPAR2 (B, E, H, K). AIA+NBQX rats showed less bone remodelling and subsequently less staining of both proteins (C, F, I, L, black arrow heads). Abundant TRAP staining was found in AIA rats (N) indicating the presence of more osteoclasts compared with naive (M) and AIA+NBQX rats (P). Consecutive sections showed expression of KA1 (E) and AMPAR2 (K) in TRAP positive osteoclasts (O) in AIA rats (blue arrows). Black boxes are shown at ×40 in images underneath. (O) ×40 Image of boxed area in N. Corresponding negative controls (no primary antibody) and rabbit IgG controls were negative for KA1 and AMPAR2 (see online supplementary figure S1). Scale bars: (A–C, G–I, M, N, P), 100 μm; (D–F, J–L, O), 50 μm.
Osteocytes and other mononuclear cells in remodelling bone expressed AMPAR2 in AIA and AIA+NBQX (figure 2K,L). NBQX reduced the extent of remodelling, with an apparent reduction of GluR positive cells (figure 2). Neither AMPAR2 nor KA1 localised to mononuclear bone cells in naive animals (figure 2). TRAP positive osteoclasts in AIA coexpressed KA1 and AMPAR2 in consecutive sections (figure 2).

GluR transcripts (except GluR5 and NMDAR1) were detected in all rat joint tissues (see online supplementary figure S4). AIA and AIA+NBQX rats showed no differences in GluR mRNA expression, except for a fivefold increase in patella AMPAR3 in AIA that remained at contralateral control levels in AIA+NBQX (p<0.05, supplementary figure S4).

**NBQX reduces inflammation and IL-6 expression**

Peak knee swelling following arthritis induction (day 1, 4.4 ±0.14 mm) was reduced in AIA+NBQX rats (2.95±0.23 mm, 33% reduction, p<0.001) and at all other time points (p<0.001, figure 3A).

Serum IL-6 was undetectable in AIA samples (<21 pg/mL). However, at day 21, a threefold increase in meniscal IL-6 mRNA in the inflamed knee of AIA rats compared with the contralateral knee (p<0.05) remained at control levels in AIA+NBQX (p<0.05, figure 3B). IL-6 mRNA was not detected in FC, FS, TP and patella.

Synovial inflammation scores were reduced by NBQX treatment (7.67±0.41 vs 5.11±0.65, p<0.001) (figure 3C). Naive animals displayed normal synovial lining, 2–4 cells thick with adipose tissue (Ad) directly beneath. The articular surface (J) consisted of a layer of smooth cartilage (Ca) over subchondral bone (Bo). (E, F) Synovial hyperplasia (pannus (P)), exudate (E), inflammatory cell infiltrate (ICI) and articular surface degradation apparent in AIA rats (H, K) was less severe in AIA+NBQX rats (I, L). MTP, medial tibial plateau; LTP, lateral tibial plateau; MFC, medial femoral condyle; LFC, lateral femoral condyle; M, meniscus. Boxes in (D–F) indicate where images in (G–L) are from. Scale bars: (D–F), 1 mm; (G–I), 50 μm; (J–L), 100 μm.

**NBQX restores weight bearing**

While AIA rats had no right hind-footprints on days 1 and 2 (figures 4A,B), NBQX restored weight bearing on these days, comparable with naive rats. Walking abnormalities occurred in AIA and AIA+NBQX rats, with greater foot rotation (figure 4B) and stance width (figure 4C) and shorter stride length (figure 4D) than naive rats (p<0.05).
**NBQX reduces joint degradation**

NBQX treatment reduced cartilage and bone pathology (figure 5). AIA caused loss of cartilage and substantial subchondral bone remodelling, whereas NBQX treated knees resembled those from naive rats, except for remodelling at the outer edges (figure 5A). NBQX reduced AIA severity score (39.3±4.6) by 27% (28.8±1.7, \( p<0.001 \)) although not to naive values (11.7±2.7, \( p<0.001 \)) (figure 5B).

While severity scores did not vary significantly across joint quadrants (MT\(_P\), lateral TP, medial FC, lateral FC), scores were lower in the whole FC following NBQX treatment (20.9±2.99 (AIA) to 12.7±0.85 (AIA+NBQX), \( p<0.01 \), figure 5C). NBQX lowered each score component, showing the greatest effect in bone (figure 5D, see online supplementary table S6). Severe bone erosions and synovial inflammation in AIA revealed by x-ray (figure 6A–C) and MRI (figure 6D–F) were attenuated by NBQX treatment.

**NBQX affects bone markers**

Threefold increases in cathepsin K mRNA (pooled FC and TP) in AIA compared with contralateral control knees (\( p<0.01 \)) was halved by NBQX (\( p<0.05 \)), but not restored to control values (\( p<0.05 \), figure 6G). COL1A1 expression was increased in AIA (\( p<0.001 \)) and AIA+NBQX (\( p<0.05 \)) compared with contralateral controls (figure 6H). Increased RANKL mRNA expression (\( p<0.05 \)) and RANKL to OPG ratios (\( p<0.01 \)) in AIA compared with contralateral controls were prevented by NBQX treatment (figure 6I,K). Neither AIA nor AIA+NBQX affected OPG mRNA expression (figure 6J).

**NBQX reduces HOB number and mineralisation**

NBQX treatment reduced HOB number at days 2 and 5 (\( p<0.001 \)) and prevented mineralisation in all cultures (see online supplementary figure S5).

**DISCUSSION**

To determine whether glutamatergic signalling influences local inflammatory processes underlying arthritic pathologies, we investigated synovial inflammation and AMPA/KA GluR expression in human OA, RA and rat AIA, and determined whether AMPA/KA GluR antagonists affect AIA pathology. Characteristic synovial inflammation occurred in all arthritis patients.\(^{30} 38 39\) AMPA and KA GluRs were expressed in inflamed synovium, and diseased areas of bone and cartilage in human arthritic tissue and rat AIA. A single intra-articular NBQX injection profoundly reduced joint pathology in AIA, reducing knee swelling by 33%, histological synovial inflammation scores by 34% and degeneration scores by 27%. The protection offered by NBQX exceeded
that of etanercept, infliximab and methotrexate in the same model. A single intra-articular injection of methotrexate at the time of induction did not reduce swelling or degeneration, and although liposomally conjugated methotrexate reduced knee swelling by 39% on day 1, long-term effects are unreported. Six intraperitoneal injections of etanercept and infliximab had milder effects on swelling than NBQX (∼20% reduction, days 1–7), and no effect on joint pathology at day 21 in rat AIA. Continuous administration of etanercept (intrathecal) and leflunomide (oral) was required to reduce joint pathology in rat AIA. Thus, NBQX treatment in the AIA model is more effective than equivalent administration of approved drugs.

This is the first report to demonstrate localisation of GluRs to bone, cartilage and synovial cells in human OA and RA tissue. This is particularly important for OA as it is a common disease, with limited therapeutic options, where current trials are testing efficacy of anti-inflammatory treatments. In human OA and RA, AMPAR2 localised to mononuclear bone cells, including osteocytes, and KA1 to osteoclasts and osteoblasts but not osteocytes in remodelling bone. Similarly, in rat AIA, mononuclear cells and TRAP stained osteoclasts in remodelling bone expressed AMPAR2 and KA1, consistent with the effects of these GluRs on osteoblast and osteoclast activities. NBQX treatment in AIA reduced bone remodelling and therefore GluR abundance. Rodent osteoblasts, osteocytes and osteoclasts express AMPAR2 protein, and osteoclasts express KA1, but there have been no reports in human bone cells. AMPAR2 was not detected in osteocytes in naive animals, consistent with previous reports, but was expressed in AIA osteocytes.

AMPAR2 and KA1 were expressed by chondrocytes in naive, AIA and AIA+NBQX rats, and in human OA and RA tissue, where GluRs were abundant near the surface and towards the mid-zone. Chondrocytes release glutamate and express AMPA and NMDA GluRs. NMDA GluR antagonists decrease proliferation and inhibit IL-1β induced increases in cyclooxygenase-2, IL-6 and MMP3 mRNA expression in chondrocytes. However, KA GluR expression and the role of AMPA/KA GluRs have not been reported in chondrocytes.

Our observation that NBQX treatment reduced knee swelling and synovial inflammation over 21 days is the first to show an effect of AMPA/KA GluR antagonists on swelling and long-lasting anti-inflammatory effects of any GluR antagonist after a single injection. A study targeting all iGluRs with a single intra-articular injection in rat CFA arthritis only reported short-term reduction of swelling. An NMDA GluR antagonist had long-term effects on paw synovitis in mouse CIA, but this required 12-hourly, intra-peritoneal injections. The anti-inflammatory effects of NBQX may be mediated by IL-6. Increased meniscal IL-6 mRNA expression in AIA was reduced by NBQX treatment, suggesting that bone, marrow and/or cartilage cells in the meniscus may respond to glutamate to produce IL-6.

NBQX treatment restored weight bearing over 2 days following AIA induction, probably reflecting reduced pain. Previous studies found that injection of MK801 (NMDAR antagonist) or NBQX into the rat knee inhibits arthritis pain for 24 h, a single intra-articular injection of combined NMDAR and AMPA/KA GluR antagonists alleviates alldynia over 3 days.
and repeated injection of AMPA GluR antagonists (0–23 h) following CFA arthritis alleviates inflammatory pain.26 However, our data are the first to demonstrate 2-day restoration of joint loading from a single intra-articular treatment of one GluR antagonist. This body of evidence indicates that peripheral inhibition of AMPA/KA GluRs reduces pain in arthritis.

This is the first study to show that a single intra-articular injection of any GluR antagonist alleviates cartilage and bone destruction in arthritis. A single intra-articular injection of combined iGluR antagonists did not affect cartilage erosion in CFA arthritis.27 While memantine (NMDAR antagonist) alleviated synovitis and joint pathology in CIA, continual 12-hourly intraperitoneal administration of the drug was necessary.21

Since AMPA/KA GluRs localised to remodelling bone in human OA, RA and rat AIA, we quantified GluR and bone cell mRNAs in joint tissues. Increased AMPAR3 mRNA expression in AIA patella was restored to normal by NBQX, and coincided with increased mRNAs reflecting osteoclast activation (RANKL), bone resorption (Cathepsin K) and bone formation (COL1A1). Cathepsin K and RANKL mRNA levels and RANKL to OPG ratio mRNA expression levels were significantly increased in the AIA inflamed knee compared with the AIA and AIA+NBOX contralateral control knees. (G, H) Cathepsin K and collagen I mRNA expression was also significantly increased in inflamed AIA+NBOX knees compared with the AIA+NBOX contralateral control. (A) A significant reduction in cathepsin K mRNA expression was found in AIA+NBOX inflamed knees compared with AIA inflamed knees. (J) There were no differences in OPG expression. *p<0.05, **p<0.01, ***p<0.001.

Consistent with this, NBQX reduced cell number and prevented mineralisation in HOBs from OA patients. Thus, the protective effect of NBQX in AIA may reflect inhibition of osteoblast activity associated with reduced RANKL mediated activation of osteoclasts. However, NBQX may also target AMPA and KA GluRs expressed by synoviocytes56 and chondrocytes57 to regulate RANKL or directly inhibit osteoclast activity.46

In conclusion, a single intra-articular injection of NBQX alleviated inflammation, pain and joint degeneration in rat AIA. Thus, AMPA/KA GluR antagonists have potential to alleviate multiple symptoms in any form of arthritis where local inflammatory processes are involved. GluR antagonists, tolerated in humans,58–60 and which do not cross the blood–brain barrier,58 61 are a timely potential therapeutic for modulating glutamatergic signalling in joints to treat arthritis.

Acknowledgements We are grateful to Derek Scarborough, Mari Nowell, Alex Klein, Eleri Jones, Samantha Lai-Morrice, Carole Elford, Helen Hodgson, Andrea Longman, Chris Wilson and Karen Brakspear for their contributions to this work.

Contributors The corresponding author confirms that all the individuals listed as authors fulfill the uniform authorship credit requirements for manuscripts submitted to medical journals, that is, that they all contributed to the manuscript based on (1) substantial contributions to conception and design, acquisition of data, or analysis
and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published.

**Funding** This work within the Arthritis Research UK Biomechanics and Bioengineering Centre was funded by Arthritis Research UK and Cardiff University, and supported by National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC).

**Competing interests** None.

**Ethics approval** Research Ethics Committee for Wales.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**


AMP/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis

Cleo S Bonnet, Anwen S Williams, Sophie J Gilbert, Ann K Harvey, Bronwen A Evans and Deborah J Mason

Ann Rheum Dis 2015 74: 242-251 originally published online October 15, 2013
doi: 10.1136/annrheumdis-2013-203670

Updated information and services can be found at:
http://ard.bmj.com/content/74/1/242

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2013/10/16/annrheumdis-2013-203670.DC1

References
This article cites 60 articles, 14 of which you can access for free at:
http://ard.bmj.com/content/74/1/242#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (604)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Immunology (including allergy) (5144)
Inflammation (1251)
Pain (neurology) (883)
Osteoarthritis (931)
Connective tissue disease (4253)
Rheumatoid arthritis (3258)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/